One of the most controversial topics in antitrust law and scholarship during the last decade or more has been what legal standards are an appropriate frame of reference for evaluating the lawfulness of so-called “reverse payments,” in which after a would-be generic drug manufacturer
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.